Pre-Admission Beta-Blocker Therapy and Outcomes of Coronavirus Disease 2019 (COVID-19): A Systematic Review, Meta-Analysis, and Meta-Regression
- 1 June 2022
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Disorders-Drug Targets
- Vol. 22 (2) , 104-117
Abstract
Background: Hypertension and heart failure are known risk factors for coronavirus disease 2019 (COVID-19) severity and mortality outcomes. Beta-blocker is one of the drugs of choice to treat these conditions. The purpose of this study is to explore the relationship between pre-admission beta-blocker use and COVID-19 outcomes. Methods: PubMed and Europe PMC were used as the database for our search strategy by using combined keywords related to our aims until December 10th, 2020. All articles related to COVID-19 and beta-blocker were retrieved. Review Manager 5.4 and Comprehensive Meta-Analysis 3 software were used to perform statistical analysis. Results: A total of 43 studies consisting of 11,388,556 patients were included in our analysis. Our meta-analysis showed that the use of beta-blocker was associated with increased risk of COVID-19 [OR 1.32 (95% CI 1.02 – 1.70), p = 0.03, I2 = 99%, random-effect modelling], clinical progression [OR 1.37 (95% CI 1.01 – 1.88), p = 0.04, I2 = 89%, random-effect modelling], and mortality from COVID-19 [OR 1.64 (95% CI 1.22 – 2.19), p = 0.0009, I2 = 94%, random-effect modelling]. Meta-regression showed that the association with mortality outcome were influenced by age (p = 0.018) and hypertension (p = 0.005). Conclusions: The risk and benefits of using beta-blocker as a drug of choice to treat hypertensive patients should be put into account and reviewed individually case by case, knowing their association in higher incidence and severity of Covid-19 infections. Other first-line antihypertensive drugs may be considered as an alternative therapy if the risk of administering beta blockers outweigh the benefits in Covid-19 infection.Keywords
This publication has 72 references indexed in Scilit:
- β-blockers and risk of all-cause mortality in patients with chronic heart failure and atrial fibrillation—a meta-analysisBMC Cardiovascular Disorders, 2019
- Beta-blockers for heart failureCochrane Database of Systematic Reviews, 2017
- Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control studyBMC Medicine, 2017
- Effect of losartan and atenolol on insulin sensitivity in nondiabetic hypertensive patientsJournal of Pharmacology and Pharmacotherapeutics, 2016
- Inflammation and Hypertension: New Understandings and Potential Therapeutic TargetsCurrent Hypertension Reports, 2014
- Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa Scale and the RTI item bankClinical Epidemiology, 2014
- β-Blockers in Hypertension: Studies and Meta-analyses Over the YearsCanadian Journal of Cardiology, 2014
- β-Blockers and Atrial Fibrillation: Hypertension and Other Medical Conditions Influencing Their UseCanadian Journal of Cardiology, 2014
- Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patientsJournal Of Hypertension, 2001
- Influence of hydroxychloroquine on the bioavailability of oral metoprololBritish Journal of Clinical Pharmacology, 2000